. Author manuscript; available in PMC: 2018 Sep 26.

Published in final edited form as: Med Res Arch. 2018 Mar 15;6(3):1719. doi: 10.18103/mra.v6i3.1719

Table 4.

Current treatment recommendations for primary CNS GCT

Germ Cell Tumors (GCT)			Recommendations
Germinomas			4 cycles of platinum based chemotherapy, usually including etoposide, ifosfamide, and either carboplatin or cisplatin^8,36,56 followed by whole ventricular radiotherapy (20-24Gy) and boost radiation (12-16) to tumor bed^57,58 if CSF metastasis detected, then craniospinal irradiation also administered^36,59,60

Non-germinomatous GCT
	teratomas
		mature	complete surgical resection^6,22,27

		immature	4–6 cycles of neoadjuvant chemotherapy, usually including carboplatin/cisplatin, etoposide, and ifosfamide, but may include gemcitabine, taxanes, or vinblastine^6,27,56; however, immature teratomas do not respond well to cisplatin²² more intensive chemotherapy regimens are recommended for worse prognosis NGGCT¹⁰ craniospinal irradiation (≥36Gy) and boost radiation (≥54Gy) to tumor bed^27,28,41 or whole brain/ventricular radiation (24-40Gy) with boost radiation (15-30Gy) to tumor bed⁴³ complete surgical resection when possible^3,6,28 Some suggest best protocol for poor prognosis NGGCT should include simultaneous radiation and chemotherapy followed by resection of remaining tumor^3,8
embryonal carcinomas
choriocarcinomas
yolk sac tumors